Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Peripheral Neuropathy Treatment Market Report 2022: Government Support for Academic Research Propels Growth | ||
By: PR Newswire Association LLC. - 04 Oct 2022 | Back to overview list |
|
DUBLIN, Oct. 4, 2022 /PRNewswire/ --The "Peripheral Neuropathy Treatment Market, by Indication, by Treatment and Non-Pharmacological Therapies, by End-user, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
Peripheral neuropathy caused by either type 1 diabetes or type 2 diabetes is called diabetic polyneuropathy. Individual with peripheral neuropathy generally describe the pain as stabbing, burning or tingling. In many cases, symptoms improve, especially if caused by a treatable condition. Medications such as Lyrica, Cymbalta, etc can reduce the pain of peripheral neuropathy. Market Dynamics Key players operating in the global peripheral neuropathy treatment market are focusing on adoption growth strategies such as product launch, and approval which are expected to drive the market growth during the forecast period. For instance, in July 2019, Alembic Pharmaceuticals Limited, an Indian pharmaceutical company, announced that it received the approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Pregabalin Capsules that is used for peripheral neuropathic pain. Moreover, various government agencies focusing on investing funds in academic research institutes focusing on the research and development for treatment of chemotherapy-induced peripheral neuropathy which is expected to drive the market growth over forecast period. For instance, in November 2018, the U.S. National Cancer Institute awarded/invested US$ 2.3 Mn in Indiana University School of Medicine, a research institute in the U.S. The investment was made in Indiana University School of Medicine to accelerate the research and development of small, targeted molecule called APX3330 to prevent or reverse chemotherapy induced peripheral neuropathy (CIPN) caused by cancer drugs. Key features of the study:
Detailed Segmentation: Global Peripheral Neuropathy Treatment Market, By Indication :
Global Peripheral Neuropathy Treatment Market, By Treatment :
Global Peripheral Neuropathy Treatment Market, By End User :
Global Peripheral Neuropathy Treatment Market, By Region Company Profiles:
Key Topics Covered: 2. Market Purview 3. Market Dynamics, Regulations, and Trends Analysis 4. Global Peripheral Neuropathy Treatment Market - Impact of Coronavirus (Covid-19) Pandemic 5. Global Peripheral Neuropathy Treatment Market, By Indication, 2017-2030, (US$ Mn) 6. Global Peripheral Neuropathy Treatment Market, By Treatment, 2017-2030, (US$ Mn) 7. Global Peripheral Neuropathy Treatment Market, By End User, 2017-2030, (US$ Mn) 8. Global Peripheral Neuropathy Treatment Market, By Region, 2017-2030, (US$ Mn) 9. Competitive Landscape 10. Section For more information about this report visit https://www.researchandmarkets.com/r/y6jh6o Media Contact: Research and Markets Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg View original content:https://www.prnewswire.com/news-releases/peripheral-neuropathy-treatment-market-report-2022-government-support-for-academic-research-propels-growth-301640649.html SOURCE Research and Markets |
||
|
||
Copyright 2022 PR Newswire Association LLC. | Back to overview list |